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Abstract
Background: Prostate cancer is one of the leading causes of cancer death in the male population. Fortunately, the
prognosis is excellent if detected at an early stage. Hence, the detection and localization of prostate cancer is crucial
for diagnosis, as well as treatment via targeted focal therapy. New imaging techniques can potentially be invaluable
tools for improving prostate cancer detection and localization.
Methods: In this study, we introduce a new form of diffusion magnetic resonance imaging called correlated diffusion
imaging, where the tissue being imaged is characterized by the joint correlation of diffusion signal attenuation across
multiple gradient pulse strengths and timings. By taking into account signal attenuation at different water diffusion
motion sensitivities, correlated diffusion imaging can provide improved delineation between cancerous tissue and
healthy tissue when compared to existing diffusion imaging modalities.
Results: Quantitative evaluation using receiver operating characteristic (ROC) curve analysis, tissue class separability
analysis, and visual assessment by an expert radiologist were performed to study correlated diffusion imaging for the
task of prostate cancer diagnosis. These results are compared with that obtained using T2-weighted imaging and
standard diffusion imaging (via the apparent diffusion coefficient (ADC)). Experimental results suggest that correlated
diffusion imaging provide improved delineation between healthy and cancerous tissue and may have potential as a
diagnostic tool for cancer detection and localization in the prostate gland.
Conclusions: A new form of diffusion magnetic resonance imaging called correlated diffusion imaging (CDI) was
developed for the purpose of aiding radiologists in cancer detection and localization in the prostate gland.
Preliminary results show CDI shows considerable promise as a diagnostic aid for radiologists in the detection and
localization of prostate cancer.
Background
Prostate cancer is the most common form of cancer diag-
nosed in men, with roughly 241,740 new cases in 2012
in the United States [1]. Furthermore, prostate cancer is
the second leading cause of cancer death in males in the
United States, with an estimated 28,170 deaths in 2012 [1].
Given that the median patient survival time for metastatic
prostate cancer ranges from 12.2 to 21.7 months [2-6],
early clinical diagnosis of prostate cancer is key to improve
the treatment of patients affected by prostate cancer. Tra-
ditionally, clinical diagnosis of prostate cancer involves
a prostate specific antigen (PSA) screening, where high
PSA levels are considered indicative of possible signs of
prostate cancer [7]. However, PSA screening has resulted
in significant over-diagnosis of men suspected of having
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prostate cancer but who do not actually require treat-
ment. As a consequence, many men are over-treated with
therapies that carry significant risks in themselves [8]. Fur-
thermore, there is still no reliable, widely acceptedmethod
of diagnostic imaging for prostate cancer. Although tran-
srectal ultrasound (TRUS) is used routinely as a guide for
biopsy, it cannot be used to visualize cancer foci because
many tumours in the prostate gland are isoechoic and
cannot be differentiated from surrounding tissue, result-
ing in sensitivity and specificity in the range of 40–50%
[9,10]. Positron emission tomography (PET) have also
been investigated as a potential imaging modality for
prostate cancer detection, with a number of different trac-
ers that have shown promise for identifying prostate can-
cer [11-14]. However, the spatial resolution achieved using
PET may not be adequate to properly localize and detect
early stage prostate cancer [15]. T2-weighted magnetic
resonance imaging (MRI) has also been investigated for
prostate cancer detection [16-18], but currently requires
© 2013 Wong et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
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highly-qualified subspecialty radiologists to interpret the
data due to its weak delineation between cancerous tissue
and healthy tissue. Furthermore, in the peripheral zone of
the prostate gland, the low T2 signal intensity that is asso-
ciated with prostate cancermay also be due to a number of
noncancerous abnormal conditions such as inflammation
and hemorrhaging [19].
A promising imaging modality for diagnosing prostate
cancer is diffusion imaging, where pairs of opposing mag-
netic field gradient pulses are applied to obtain sensitivity
to the Brownian motion of water molecules in tissues [20].
The differences in diffusion characteristics between tissue
types facilitate for tissue characterization. As such, given
the presumed high cellular density of prostate cancer,
the associated tissues should exhibit restricted diffusion
characteristics (and as such should have lower apparent
diffusion coefficient (ADC) values). While diffusion imag-
ing shows considerable promise [21-23], particularly when
used in multi-parametric imaging scenarios [24,25], delin-
eating between cancerous tissue and healthy tissue in
the prostate gland remains a challenge, due partly to the
necessity for fine-tuning the strength, duration, and tim-
ing of the applied diffusion gradient pulses. Other chal-
lenges include the multifocality of prostate cancer [26], as
well as the relatively small size of a majority of prostate
cancer tumors. Hence, the characteristics between can-
cerous tissue and healthy tissue may appear to have sub-
stantial overlap depending on the way the gradient pulses
are applied, thus making it difficult to detect and localize
prostate cancer. As such, an alternative form of magnetic
resonance imaging that gets around this issue is highly
desired.
The main contribution of this study is the introduction
of a new form of diffusion magnetic resonance imag-
ing called correlated diffusion imaging (CDI), which takes
advantage of the joint correlation in signal attenuation
across multiple gradient pulse strengths and timings to
not only reduce the dependency on the way diffusion
gradient pulses are applied, but also improve delineation
between cancerous and healthy tissue. To the best of the
authors’ knowledge, there are no previous imaging tech-
niques that take this type of approach to prostate cancer
assessment.
Methods
The methodology behind correlated diffusion imaging
(CDI) is summarized in Figure 1. First, multiple sig-
nal acquisitions are conducted at different gradient pulse
strengths and timings. Second, the acquired signals are
then mixed together to obtain the local correlation of
signal attenuation across the acquired signals, which pro-
duces a final signal that characterizes the tissue being
imaged. A detailed description of the steps involved is
presented below.
Imaging protocol
To evaluate the effectiveness of CDI for prostate cancer
diagnosis, twenty patient cases with known prostate can-
cer were used in this study. The patients ranged in age
from 58–80 years, with amedian age of 69 years. Informed
consent was obtained from all patients, and approval for
this study was obtained from the ethics review board
of Sunnybrook Health Sciences Centre. All results were
reviewed by an expert radiologist with 16 years of expe-
rience interpreting body MRI and 11 years of experience
interpreting prostate MRI.
Examinations using CDI were performed using a Philips
Achieva 3.0T machine at Sunnybrook Health Sciences
Centre, Toronto, Canada. The axial echo-planar sequence
was performed for CDI with the following imaging param-
eters: TR range from 3336–6178 ms with a median of
4890 ms, and TE ranged from 61–67 ms with a median
of 61 ms. The resolution of the signal acquisitions ranged
from 1.36×1.36 mm2 to 1.67×1.67 mm2, with a median of
1.56×1.56 mm2. Slice thickness ranged from 3.0–4.0 mm
with a median of 3.5 mm. The display field of view
(DFOV) ranged from 20×20 cm2 to 24×24 cm2 with a
median of 24×24 cm2.
Figure 1 The methodology behind correlated diffusion imaging. The methodology behind correlated diffusion imaging (CDI) can be
summarized as follows. First, multiple signal acquisitions are conducted using sequences with different gradient pulse strengths and timings
(q1, q2,. . . , qN). Second, the acquired signals (S1, S2, . . . , SN) are then mixed together to obtain the local correlation of signal attenuation across the
acquired signals, which produces a final signal (C) that characterizes the tissue being imaged.
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For comparison purposes, apparent diffusion coefficient
(ADC) maps were also obtained using the same axial
echo-planar sequence with the same imaging parame-
ters and  = {0s/mm2, 100s/mm2, 1000s/mm2}, as it is
considered state-of-the-art for prostate cancer analysis in
existing diffusion imaging [24]. Finally, axial T2-weighted
imaging acquisitions with the same slice locations as the
CDI sequence were obtained as a baseline reference of
comparison. Examinations using T2-weighted imaging
were performed using a Philips Achieva 3.0T machine
with the following imaging parameters: TR range from
4688–7504 ms with a median of 6481 ms, and TE range
from 110–120ms with a median of 120ms. Slice thickness
ranged from 3.0–4.0 mm with a median of 3.5 mm. The
display field of view (DFOV) ranged from 20×20 cm2 to
24×24 cm2 with a median of 24×24 cm2.
Signal acquisition
As the first step of the CDI imaging process, axial single-
shot echo-planar sequences with two gradient pulses of
equal magnitude (one pulse in each side of the 180o pulse
to dephase and rephrase the spins, respectively), as shown
in Figure 2 are used to obtain multiple signal acquisi-
tions using a set of different configurations of gradient
pulse strengths and timings, which we will denote as  =
{qi|i = 1, ...,N}, where qi denotes the ith sequence.
Imperfect rephasing occurs due to motion of water
molecules, leading to attenuation in the acquired signal
and thus allowing for the study of water diffusion based
on signal attenuation behavior. By varying the configu-
ration of gradient pulse strengths and timings between
signal acquisitions, each signal acquisition is sensitive to
a different degree of Brownian motion of water molecules
in tissues, thus providing unique information with respect
to the water diffusion characteristics of the tissue being
imaged. The different configurations of gradient pulse
strengths and timings can be defined by the following set
of parameters [27]:
qi = (Gi, δi,i), (1)
where, for the ith sequence, Gi denotes the gradient pulse
strength, δi denotes the gradient pulse duration, and
i denotes time between gradient pulses. By grouping
the gradient terms, the configuration of gradient pulse
Figure 2 Echo-planar sequence with two gradient pulses.
Echo-planar sequence with two gradient pulses (G1 and G2) of equal
magnitude (one pulse in each side of the 180o pulse to dephase and
rephase the spins).
strengths and timings used for a particular sequence qi
can be simplified to [28]
qi = γ 2G2i δ2i (i −
δi
3 ), (2)
where γ denotes the proton gyromagnetic ratio.
Signal mixing
As the second step of the CDI imaging process, the mul-
tiple signal acquisitions are mixed together to obtain the
final signal that characterizes the tissue being imaged.
Here, we are interested not in the signal attenuation
obtained using the individual configurations of gradient
pulse strengths and timings, but in the local correlation
of signal attenuation across the different configurations
of gradient pulse strengths and timings within a local
spatial sub-volume V to provide a better overall charac-
terization of the water diffusion properties of the tissue
being imaged. As such, we would like to mix all of the sig-
nal acquisitions together into a single quantitative signal
characterizing the local signal attenuation correlation.
To achieve this goal, we introduce the following signal
mixing function C(x) for characterizing local signal atten-










Sqα (x) . . . Sqβ (x)f
(
Sqα (x), . . . , Sqβ (x)|V (x)
)
× dSqα (x) . . . dSqβ (x),
(3)
where x denotes spatial location, S denotes the acquired
signal, f denotes the conditional joint probability
Figure 3 Receiver operator characteristic (ROC) curves. Receiver
operator characteristic (ROC) curves from all patient cases for
detection of prostate cancer using CDI (blue line) and ADC map (red
line). For whole prostate, the area under the ROC curve (Az ) was
higher for CDI (Az = 0.9789) than for ADC map (Az = 0.9183).
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Table 1 Leave-one-out cross-validation (LOOCV) results
Sensitivity Specificity Accuracy
CDI 0.8676 0.9444 0.9363
ADC 0.8236 0.7679 0.7691
density function, and V (x) denotes the local sub-







, and V was defined as a 7 mm3
spatial sub-volume for assessment purposes as it was
found to provide good tissue delineation.
Image analysis and interpretation
The ADCmaps and CDI images were reconstructed using
the ProCanVAS (Prostate Cancer Visualization andAnaly-
sis System) platform developed at the University ofWater-
loo Vision and Image Processing research group, and were
analyzed such that each modality was analyzed indepen-
dent of othermodalities. All visual assessments weremade
by an expert radiologist with 16 years of experience inter-
preting body MRI and 11 years of experience interpreting
prostate MRI.
Statistical analysis
Two different analysis strategies were performed to quan-
tify the potential of CDI as a tool for prostate cancer
detection and localization. In the first analysis strategy,
a receiver operating characteristic (ROC) curve analysis
was performed using CDI to quantitatively assess prostate
detection and localization. The ROC curves were esti-
mated assuming bivariate normal data. For illustrative
purposes, the ROC curves obtained from the pooled data
of all patient cases was plotted. To provide a quantita-
tive assessment of diagnostic accuracy, the area under the
ROC curve (Az) was obtained as a single metric of diag-
nostic accuracy. For comparison purposes, ROC curve
analysis was also performed using ADC map as the base-
line reference method for assessing prostate cancer using
diffusion imaging.
In the second analysis strategy, we wish to study whether
CDI would be a useful imaging modality for building
computer-aided clinical decision support systems to assist
in the prostate cancer detection and localization pro-
cess. To quantify the usefulness of CDI for the purpose
of building such systems, leave-one-out cross-validation
(LOOCV) trials were performed across all patient cases.
For each trial, a two-class Maximum Likelihood (ML)
classifier model is trained based on the CDI signal inten-
sity statistics of the individual voxels within the prostate
gland (one class characterizing cancerous tissue, with the
other class characterizing healthy tissue) across the train-
ing patient cases. This learned two-class ML classifier
model is then used to calculate sensitivity, specificity, and
accuracy for the validation patient case. This process is
repeated for a number of trials so that each patient case
is used once as the validation patient case. The same was
performed on ADC for comparative purposes.
Results and discussion
To visualize the diagnostic performance for all patient
cases, ROC curves for CDI and ADC map results from all
patient cases are shown in Figure 3. It can be observed that
improved ROC characteristics are exhibited by CDI when
compared to ADC map. Furthermore, the area under the
ROC curve for CDI is higher with Az = 0.9789, compared
to the ROC curve for ADC map with Az = 0.9183. The
overall sensitivity, specificity, and accuracy results from
the LOOCV trials are shown in Table 1. It can be observed
that the sensitivity, specificity, and accuracy are higher for
CDI when compared to ADC, which indicates the poten-
tial usefulness of CDI as an imaging modality for building
computer-aided clinical decision support systems to assist
in the prostate cancer detection and localization process.
Figures 4, 5 and 6 show example slices from T2-
weighted imaging, ADC map, and CDI of five patient
cases out of the twenty patient cases used in the ROC anal-
ysis, and a number of observations can be made. Note that
example slices show cancerous regions within the prostate
gland, not benign prostatic hyperplasia (BPH) nodules.
Figure 4 Example case 1. Tumor stands out well on CDI and not at all on T2-weighted imaging in patient with prostate cancer. a), T2-weighted
imaging shows no change in signal towards left side of transition zone. b), ADC map shows increased contrast around left side of transition zone.
c), CDI shows very high signal intensity corresponding to left side of transition zone.
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Figure 5 Example case 2. Tumor stands out well on CDI and not at all on T2-weighted imaging in patient with prostate cancer. a), T2-weighted
imaging shows no change in signal towards left side of transition zone. b), ADC map shows increased contrast around left side of transition zone.
c), CDI shows very high signal intensity corresponding to left side of transition zone.
There is weak visual delineation between prostate can-
cer and healthy tissue in the prostate gland in the
T2-weighted imaging, thus making it difficult even
for highly-qualified subspecialty radiologists to interpret
(particularly in Figures 4 and 5 where there is no decrease
in signal in the cancerous region). The ADCmap provides
improved visual delineation compared to the T2-weighted
imaging; however, it can be observed that there are some
cases (e.g., Figure 6) where the boundary delineation
between tumor and healthy tissue is still difficult to assess.
The CDI provides clearer indication of the locations and
boundaries of the prostate cancer compared to the ADC
maps for all patient cases. Hence, these preliminary results
are motivating for the potential of CDI as a diagnostic tool
for prostate cancer detection and localization.
Discussion
In this study, we have introduced a new form of diffusion
magnetic resonance imaging called correlated diffusion
imaging, which quantifies joint correlation in signal atten-
uation across multiple diffusion gradient pulse strengths
and timings. The preliminary results in this study show
that CDI has potential to be an effective tool for prostate
cancer detection and localization.
It is important to also understand the merits of
CDI in relation to practical aspects of clinical image
acquisition, post-processing, and analysis. One of the
attractive characteristics of CDI from a clinical image
acquisition perspective is that the signal acquisition
process of CDI can be performed on existing clini-
cal imaging systems without hardware modifications.
The signal mixing and reconstruction process of CDI
can all be performed post-acquisition on a com-
puter workstation using additional computer-aided clin-
ical decision support software such as the ProCanVAS
(Prostate Cancer Visualization and Analysis System) plat-
form developed at the University of Waterloo Vision and
Image Processing research group. Therefore, the only
additional resources needed for practical clinical imag-
ing using CDI compared to other modalities is the need
for software to reconstruct the CDI images. Once recon-
structed, the CDI images can be viewed on any existing
DICOM viewer software, making it easy to integrate into
existing radiology workflows.
One possible explanation for CDI’s potential to be a
more effective tool for prostate cancer detection and
localization when compared to standard clinical practice
ADC maps may be related to the highly restrictive water
diffusion nature of prostate cancer. While different gra-
dient pulse strengths and timings may be more sensitive
to different degrees of water diffusion motion, this highly
restrictive diffusion nature results in signal attenuation
Figure 6 Example case 3. Tumors stand out well on CDI and poorly on T2-weighted imaging in patient with prostate cancer. a), T2-weighted
imaging shows mild decrease in signal towards left side of transition zone. b), ADC map shows increased contrast around both sides of transition
zone. c), CDI shows very high signal intensity corresponding to both sides of transition zone.
Wong et al. BMCMedical Imaging 2013, 13:26 Page 6 of 7
http://www.biomedcentral.com/1471-2342/13/26
that is similar or lower than healthy tissue at all degrees of
sensitivity. Therefore, this results in consistently low sig-
nal attenuation of prostate cancer compared with healthy
tissue irrespective of gradient pulse strengths and tim-
ings which, in combination with the possible higher water
content of cancerous tissue compared to healthy tissue
[29], may lead to improved cancer and healthy tissue
delineation in CDI.
A limitation of this study is the lack of substantial whole-
mount histopathology as a reference standard to establish
radiologic-pathologic correlation in a very comprehensive
manner. Therefore, given these promising preliminary
results, we suggest that CDI may be more thoroughly
investigated for prostate cancer detection and localiza-
tion, with a larger patient study that includes patient
cases with known prostate cancer, healthy patient cases,
and patient cases with benign prostatic hyperplasia (BPH)
nodules (which can be mistaken for cancer under cer-
tain imaging modalities), an assessment of inter-observer
variability, as well as comprehensive radiologic-pathologic
correlation with a much larger set of prostate whole-
mounts. Furthermore, given the potential of CDI as an
effective tool for prostate cancer detection and localiza-
tion, we suggest that studies be performed for other forms
of cancers such as pancreatic cancer, breast cancer [30],
and liver cancer [31], which may also show similar highly
restricted water diffusion characteristics.
Conclusions
In this study, a new form of diffusion magnetic resonance
imaging called correlated diffusion imaging (CDI) was
developed for the purpose of aiding radiologists in cancer
detection and localization in the prostate gland. Prelim-
inary results show CDI shows considerable promise as a
diagnostic aid for radiologists in the detection and local-
ization of prostate cancer. As such, given the promising
results of this initial study, a future direction is to perform
a larger, more comprehensive patient study to better eval-
uate the utility of CDI for the purpose of prostate cancer
detection and localization.
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